Detroit Free Press: Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for Skinject(TM) in Patients with Gorlin Syndrome Gorlin Syndrome, also known as Nevoid Basal Cell Carcinoma Syndrome, is a rare inherited genetic disorder affecting 1 in 31,000 people worldwide that can develop 500-1000 Basal Cell Carcinoma (BCC) ... Medicus Pharma Ltd.
Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for Skinject(TM) in Patients with Gorlin Syndrome Seeking Alpha: Sol-Gel Technologies Ltd to Host Virtual KOL Event on Gorlin Syndrome and the Upcoming Phase 3 Trial for SGT-610 Event to be held on will focus on preventing basal cell carcinomas associated with Gorlin syndrome with a discussion of the disease burden, SGT-610 and the upcoming Phase 3 trial NESS ... Sol-Gel Technologies Ltd to Host Virtual KOL Event on Gorlin Syndrome and the Upcoming Phase 3 Trial for SGT-610 ascopubs.org: Gorlin Syndrome: Assessing Genotype-Phenotype Correlations and Analysis of Early Clinical Characteristics as Risk Factors for Disease Severity Gorlin Syndrome: Assessing Genotype-Phenotype Correlations and Analysis of Early Clinical Characteristics as Risk Factors for Disease Severity MSN: Medicus Pharma Partners With Gorlin Syndrome Alliance to Expand Access to SKINJECT PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) has entered a strategic collaboration with the Gorlin Syndrome Alliance (GSA) to advance compassionate access to SKINJECT™, its investigational ... Medicus Pharma Partners With Gorlin Syndrome Alliance to Expand Access to SKINJECT
